Zhitong Finance App News, Changchun Hi-Tech (000661.SZ) issued an announcement. Recently, Changchun Jinsai Pharmaceutical Co., Ltd. (“Jinsai Pharmaceutical”), the holding subsidiary of the company, received the “Notice of Acceptance” approved and issued by the State Drug Administration, and the registration clinical trial application for domestically produced drugs of Jinsai Pharmaceutical GenSci161 injection was accepted. GenScI 161 injection is a new therapeutic biological product class 1 drug independently developed by Jinsai Pharmaceutical. It is a novel all-human monoclonal IgG1 bispecific antibody, intended for the treatment of pyoderma gangrenosum (PG) and cold pyrine associated periodic syndrome (CAPS).

Zhitongcaijing · 1d ago
Zhitong Finance App News, Changchun Hi-Tech (000661.SZ) issued an announcement. Recently, Changchun Jinsai Pharmaceutical Co., Ltd. (“Jinsai Pharmaceutical”), the holding subsidiary of the company, received the “Notice of Acceptance” approved and issued by the State Drug Administration, and the registration clinical trial application for domestically produced drugs of Jinsai Pharmaceutical GenSci161 injection was accepted. GenScI 161 injection is a new therapeutic biological product class 1 drug independently developed by Jinsai Pharmaceutical. It is a novel all-human monoclonal IgG1 bispecific antibody, intended for the treatment of pyoderma gangrenosum (PG) and cold pyrine associated periodic syndrome (CAPS).